Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02748668 · ClinicalTrials.gov registry record
Extracorporeal Membrane Oxygenation (ECMO): Blood Cells
A clinical trial, sponsored by Corewell Health West.
- Terminated
- Registry status
- 371
- Enrollment target
NCT02748668: Clinical Trial study, sponsored by Corewell Health West.
NCT02748668 is a clinical trial that was terminated before completion, run by Corewell Health West. The registered enrollment target is 371 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02748668 was terminated before completion, sponsored by Corewell Health West.
- TERMINATED
- Registry status
- 371 participants
- Enrollment target
Study Summary
The objective of the study is to predict outcomes of patients on extracorporeal membrane oxygenation (ECMO) therapy by correlating cytokines and inflammatory cell patterns to clinical outcomes using data collected in the ECMO Registry at Spectrum Health.
Interventions
- OTHER Blood specimen collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 371 participants |
| Start Date | 2015-01-20 |
| Est. Completion | 2023-08-23 |
Why NCT02748668 stopped before completion
NCT02748668 is an observational study that tracks outcomes without assigning an intervention. The registered 371 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Blood specimen collection is the first listed.
NCT02748668 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02748668 about?
NCT02748668 is a clinical study titled "Extracorporeal Membrane Oxygenation (ECMO): Blood Cells". The objective of the study is to predict outcomes of patients on extracorporeal membrane oxygenation (ECMO) therapy by correlating cytokines and inflammatory cell patterns to clinical outcomes using data collected in the ECMO Registry at Spectrum Health.
What is the current status of trial NCT02748668?
This trial is currently terminated. The enrollment target is 371 participants. The study started on 2015-01-20. Estimated completion is 2023-08-23.
What interventions are being tested in trial NCT02748668?
The interventions under investigation include: Blood specimen collection (OTHER).
Who is sponsoring clinical trial NCT02748668?
This trial is sponsored by Corewell Health West, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05743673 · 371 participants
SHAPE Test for Preoperative Risk Stratification
- NCT05761847 · 371 participants · NA
Pediatric Medication Therapy Management Trial
- NCT04801589 · 372 participants · Phase 3
Goal-Directed Sedation in Mechanically Ventilated Infants and Children
- NCT04879329 · 372 participants · Phase 2
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI